Literature DB >> 17437665

Cardiovascular risk, hypertension, and NSAIDs.

William B White1.   

Abstract

During the past 2 years, a great deal of evaluation has been conducted on the cardiovascular (CV) effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase (COX)-2 inhibitors. This review focuses on the effects of the NSAIDs and COX-2 inhibitors on blood pressure and CV events. Clinical trial databases for NSAIDs and COX-2 inhibitors have shown varying levels of destabilization of blood pressure control in treated hypertensive patients as well as variable incident rates of the development of arrhythmias, congestive heart failure, myocardial infarction, and stroke. Nonselective and COX-2 selective NSAIDs can be used carefully in arthritis patients with hypertension and stable CV disorders (excluding congestive heart failure and moderate to severe kidney dysfunction) when the individual clinical benefit of anti-inflammatory therapy outweighs the CV and gastrointestinal risk.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17437665     DOI: 10.1007/s11926-007-0020-3

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  68 in total

1.  Hypertension and cyclooxygenase-2 inhibitors: target: the renal medulla.

Authors:  Chuan-Ming Hao; Matthew D Breyer
Journal:  Hypertension       Date:  2004-08-16       Impact factor: 10.190

2.  Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial.

Authors:  Michael E Farkouh; Howard Kirshner; Robert A Harrington; Sean Ruland; Freek W A Verheugt; Thomas J Schnitzer; Gerd R Burmester; Eduardo Mysler; Marc C Hochberg; Michael Doherty; Elena Ehrsam; Xavier Gitton; Gerhard Krammer; Bernhard Mellein; Alberto Gimona; Patrice Matchaba; Christopher J Hawkey; James H Chesebro
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

3.  Discontinuation of nonsteroidal anti-inflammatory drug therapy and risk of acute myocardial infarction.

Authors:  Lorenz M Fischer; Raymond G Schlienger; Christian M Matter; Hershel Jick; Christoph R Meier
Journal:  Arch Intern Med       Date:  2004 Dec 13-27

4.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

5.  The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults.

Authors:  Linda E Lévesque; James M Brophy; Bin Zhang
Journal:  Ann Intern Med       Date:  2005-04-05       Impact factor: 25.391

6.  Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction.

Authors:  Raymond G Schlienger; Hershel Jick; Christoph R Meier
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

7.  Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis.

Authors:  A G Johnson; T V Nguyen; R O Day
Journal:  Ann Intern Med       Date:  1994-08-15       Impact factor: 25.391

8.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

9.  Opposite effects of cyclooxygenase-1 and -2 activity on the pressor response to angiotensin II.

Authors:  Zhonghua Qi; Chuan-Ming Hao; Robert I Langenbach; Richard M Breyer; Reyadh Redha; Jason D Morrow; Matthew D Breyer
Journal:  J Clin Invest       Date:  2002-07       Impact factor: 14.808

10.  Effects of COX inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics.

Authors:  Munavvar Izhar; Tunji Alausa; Amy Folker; Elena Hung; George L Bakris
Journal:  Hypertension       Date:  2004-01-26       Impact factor: 10.190

View more
  7 in total

1.  Use of non-steroidal anti-inflammatory drugs and risk of incident myocardial infarction and heart failure, and all-cause mortality in the Australian veteran community.

Authors:  Arduino A Mangoni; Richard J Woodman; Paraskevi Gaganis; Andrew L Gilbert; Kathleen M Knights
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

2.  Drug interactions in general dental practice--considerations for the dental practitioner.

Authors:  B E S Dawoud; A Roberts; J M Yates
Journal:  Br Dent J       Date:  2014-01       Impact factor: 1.626

Review 3.  Nonsteroidal Anti-inflammatory Drugs and Risk of Incident Heart Failure: A Systematic Review and Meta-analysis of Observational Studies.

Authors:  Patompong Ungprasert; Narat Srivali; Charat Thongprayoon
Journal:  Clin Cardiol       Date:  2015-12-31       Impact factor: 2.882

Review 4.  Prime Drug Interplay in Dental Practice.

Authors:  Sumedha Mohan; Vivek Govila; Ashish Saini; Sunil Chandra Verma
Journal:  J Clin Diagn Res       Date:  2016-03-01

5.  Prevalence, awareness, treatment, and control of hypertension in older people: results from the population-based KORA-age 1 study.

Authors:  Samuel Muli; Christa Meisinger; Margit Heier; Barbara Thorand; Annette Peters; Ute Amann
Journal:  BMC Public Health       Date:  2020-07-02       Impact factor: 3.295

6.  Efficacy and safety of ozonated autohemotherapy in patients with hyperuricemia and gout: A phase I pilot study.

Authors:  Lian-Yun Li; Jia-Xiang Ni
Journal:  Exp Ther Med       Date:  2014-09-09       Impact factor: 2.447

Review 7.  Different Chemical Structures and Physiological/Pathological Roles of Cyclooxygenases.

Authors:  Yalcin Faki; Ayse Er
Journal:  Rambam Maimonides Med J       Date:  2021-01-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.